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Efficacy of FK 506 in the Treatment of Recalcitrant 
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J.J. Fung, S. Todo, and T.E. Starzl 
I N THIS STUDY the efficacy and safety of systemic FK 506 therapy was evaluated in four patients with severe 
recalcitrant pyoderma gangrenosum unresponsive to con-
ventional therapy. 
CASE MATERIAL 
The clinical features in these four cases are summarized in Table 
1. The patients were males between the ages of 26 and 34 years. 
The duration ofthe disease ranged from 3 to 28 years. All patients 
were referred to our center with well-established clinical and 
histopathological diagnosis of the disease. Multiple large necrotic 
ulcers existed in the lower extremities (n = 4). trunk (n = 2). and 
face (n = 2) prior to FK 506 treatment. The associated clinical 
conditions. which had also resisted different kinds of therapy. are 
summarized in Table I. Interestingly, all four patients had con-
comitant inflammatory arthritis, regional enteritis (two examples), 
andlor connective tissue diseases (Table I). Patient 4 was the first 
patient ever reported with streaking leukocyte factor syndrome, 
published in 1975 by Jacobs and Goetz!.' 
FK 506 was started orally at a dose of 0.15 mg/kg twice daily. 
Dose adjustments were guided by FK 506 plasma levels or by 
clinical evidence of incomplete disease control or drug toxicity. 
Twelve-hour FK 506 trough plasma levels were measured with an 
enzyme-linked immunoassay. 2 Pre-existing steroid therapy (Table 
I) was tapered in all patients after starting FK 506 and completely 
discontinued in three patients. Other previously used immunosup-
pressive agents were discontinued before initiation of FK 506 
therapy. 
Dennatologic and medical examinations were performed re-
peatedly. Assessments included pain, erythema. and drainage 
from pyoderma gangrenosum lesions. The arthritic manifestations 
were completely evaluated by a rheumatologist. Renal function. 
serum cholesterol. blood glucose, and electrolytes were moni-
tored. If it developed, hyperkalemia was controlled with the 
mineralocorticoid fludrocortisone acetate. Hypomagnesemia was 
seen but did not require correction. 
RESULTS 
Response of the Skin Lesions 
All four patients had a dramatic initial response to treat-
ment with a marked reduction in pain. erythema. and 
drainage by one week. Complete clinical remission and 
healing of the disfiguring open sores was achieved in 
patients 2 through 4 within 4 to 8 weeks after initiation of 
FK 506 therapy (Fig 1). FK 506 plasma trough levels were 
maintained in these patients at 0.5 to 1.5 ngimL. 
Patient I was removed from the study after 4 weeks and 
returned to cyclosporine (Cy A) because of his refusal to 
undergo rehabilitation for street-drug addiction. He com-
mitted suicide a few weeks later. He had been improved by 
FK 506. The remission has been sustained in the other 
three patients for 3 to 16 months. In patient 2. efforts to 
reduce FK 506 dosage by half resulted in low drug plasma 
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Table 1. Patients With Pyoderma Gangrenosum Treated With FK 506* 
Creatinine 
Duration of Data (mg%) 
Age/Sex Disease Associated Clinical FK506 
No. (y) (y) Disease Previous Treatment Started Remission Before Alter 
2B1male 3 ulcerative colitis arthritis steroids*, Daposone. Azathio- 12/22/89 partialt 1.5 1.7 
prine. Leukeran. CyA 
2 29/male 11 Crohn's disease with perianal steroids*, Dapsone. 6-mereap- 4/4190 complete 0.5 1.2 
fistulae polyarthritiS Sjogren topurine CyA 
syndrome 
3 34/male 7 ankylosing spondylitis scleritis steroids', Dapsone 10/29190 complete 0.7 1.2 
4 311male 28 erosive polyarthritis streaking Thalidomide. steroids*, Dapsone, 5/9191 complete 0.7 1.4 
leukocyte factor Tetracycline. Colchicine 
"Follow-up 10 August 20, 1991. 
tPatient was noncompliant and stopped taking FK 506. 
*The preexISting prednisone doses were 65 :!: 35 (S.D.) mgld. In patients 2--4 the values were 40,100. and 100 mgld. These were reduced to 0,0 and 5 mgld after 
2103 weeks. 
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Fig 1. (A) This picture shows a large necrotic ulcer on the medial aspect of the left knee region of patient 2 before starting FK 506 therapy. 
(8) Marked improvement and healing of the ulcer was noted within 1 week after initiation of FK 506 treatment. 
levels and consequently in beginning reappearance of the 
skin lesions and the arthritis, which completely disap-
peared after returning to the full dose. Overall, the pro-
ductivity and the quality of life of patients 2--4 were 
significantly improved. 
Effect on Extra-Dermal Lesions 
Improvement of arthritis occurred simultaneously in pa-
tients 2 through 4. Discontinuance of steroids was consid-
ered a godsend by all patients and was particularly impor-
tant for patient 4, who has osteoporotic lesions and bone 
deformity. Two patients with concomitant inflammatory 
bowel disease became asymptomatic within 4 weeks after 
FK 506 treatment. One of these patients had complete 
healing of mUltiple perianal fistulae within 6 weeks. Patient 
3 had complete disappearance of scleritis within 1 week 
after starting FK 506 treatment. 
FK 506 Adverse Effects 
Toxicity, including hyperkalemia and hypomagnesemia, 
was similar to that in the psoriasis patients. 3 There were 
increases in the current serum creatinine and B UN (Table 
1) despite careful dose contro!' -N;pne of the patients 
developed systemic arterial hypertension after initiation of 
FK 506 therapy. 
DISCUSSION AND CONCLUSION 
This study has shown the efficacy of FK 506 as monother-
apy for patients with severe pyoderma gangrenosum. The 
response was complete in all three patients who continued 
to receive the drug. The doses and plasma levels needed to 
maintain remission were in the same range as those re-
quired to prevent allograft rejection. Attempts at dose 
reduction in one patient resulted in temporary reactivation 
of the skin lesions. The long-term riskibenefit ratio of FK 
506 therapy remains to be determined. However. the 
results of the current report are unequivocally encourag-
ing. 
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